Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Positive pre-clinical data published with ReNeuron Group Plc's stem cells for retinal degenerative diseases


Tuesday, 21 Jan 2014 02:00am EST 

ReNeuron Group Plc:Says the publication in a peer-reviewed scientific journal of key pre-clinical efficacy data with its human retinal progenitor cells (hRPCs) in a model of retinal degeneration.Says in the study, ReNeuron's hRPCs were found to protect visual function when transplanted into the well-established Royal College of Surgeons (RCS) rat model of retinal degeneration.Says the hRPC-grafted eyes had significantly superior visual acuity compared with untreated eyes and histological analysis showed a significantly greater preservation of the outer nuclear layer of the retina in the treated animals.Says the first clinical application for ReNeuron's hRPCs is the company's ReN003 programme targeting the inherited, blindness-causing disease, retinitis pigmentosa.Says this programme benefits from Orphan Drug designation in both the US and Europe.Says the company and its collaborators are currently completing late pre-clinical development of the ReN003 therapy, ahead of an initial clinical trial application planned for later this year. 

Company Quote

5.625
0.0 +0.00%
11:29am EDT